Anthony's questions to Trevi Therapeutics Inc (TRVI) leadership • Q1 2025
Question
Anthony, on behalf of Ryan Deschner, asked if the company had observed any trends in the RIVER study data related to patient baseline characteristics, such as background therapies or initial disease etiology.
Answer
Chief Development Officer Dr. James Cassella stated that while the team is analyzing all the data, he did not have a definitive answer on such trends at this time. Executive Jennifer Good added that the drug demonstrated a strong effect across the board, making it difficult to identify specific subgroups where it worked differently.